HHM Wealth Advisors’s BriaCell Therapeutics BCTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$26 Hold
6
– – ﹤0.01% 958
2026
Q2
$20 Hold
6
– – ﹤0.01% 892
2026
Q1
$26 Hold
6
– – ﹤0.01% 868
2025
Q4
$43 Hold
6
– – ﹤0.01% 840
2025
Q3
$66 Sell
6
-1
-14% -$11 ﹤0.01% 844
2025
Q2
$195 Hold
7
– – ﹤0.01% 843
2025
Q1
$241 Hold
7
– – ﹤0.01% 894
2024
Q4
$565 Hold
7
– – ﹤0.01% 911
2024
Q3
$1.24K Hold
7
– – ﹤0.01% 722
2024
Q2
$1.14K Buy
+7
New +$1.98K ﹤0.01% 729

Other funds holding BCTX

HHM Wealth Advisors's BCTX Position: Q3 2026 in Review

HHM Wealth Advisors held its BriaCell Therapeutics (BCTX) position steady in Q3 2026 at 6 shares worth $26. The position accounts for ﹤0.01% of the portfolio, ranked #958.

HHM Wealth Advisors first reported a position in BCTX in Q2 2024 and has held it in 10 quarters since. The position peaked at $1.24K in Q3 2024. 19 funds tracked by Wall St. Rank hold BCTX as of Q3 2026.

  • HHM Wealth Advisors held 6 shares of BriaCell Therapeutics worth $26 as of Q3 2026.
  • HHM Wealth Advisors left its BriaCell Therapeutics share count unchanged in Q3 2026.
  • BriaCell Therapeutics made up ﹤0.01% of HHM Wealth Advisors's portfolio in Q3 2026, its #958 holding.
  • HHM Wealth Advisors first reported a position in BriaCell Therapeutics in Q2 2024 and has held it in 10 quarters since.
  • HHM Wealth Advisors's BriaCell Therapeutics position peaked at $1.24K in Q3 2024.
  • 19 funds tracked by Wall St. Rank held BriaCell Therapeutics as of Q3 2026.

Based on HHM Wealth Advisors's 13F filing for Q3 2026, filed 10 Nov 2026.